Donny Wong, Ph.D., analyst at Decision Resources, is available to discuss the impact of the Food and Drug Administration's (FDA) approval of Merck's Januvia (sitagliptin) for the treatment of type 2 diabetes.

Dr. Wong is the author of the new Emerging Therapies in Type 2 Diabetes report from Decision Resources which covers Januvia as well as Novartis's Galvus, which is in the same class, has nearly an identical clinical profile to Januvia, and will likely be approved by November 30, 2006.

  Dr. Wong can discuss the following issues:    * As the first agent in the novel class of DPP-IV inhibitors, Merck's     Januvia will lead the way in growing the type 2 diabetes market from $12      billion in 2005 to over $18 billion in 2010. Dr. Wong can provide     peak-year sales for Januvia.    * Januvia is the first oral drug targeting the incretin pathway. The very     first drug targeting this pathway, Amylin/Eli Lilly's Byetta, has had     tremendous success in the market despite its twice-daily injectable     formulation. Dr. Wong can discuss how Januvia will capitalize on the     success of Byetta.    * Januvia's safety and side effect profile, and how it compares to the     current market leaders Avandia and Actos, and the insulins.    * How Januvia may have a profound impact on medical practice for type 2     diabetes by delaying the progression of the disease.  

Donny Wong, Ph.D., is a research analyst at Decision Resources where he analyzes pharmaceutical markets for metabolic diseases such as obesity, type 2 diabetes, metabolic syndrome, and osteoporosis. He has more than 12 years of experience in scientific research and has co-authored nine peer-reviewed articles and reviews. Dr. Wong attended MIT and Williams College and earned M.M.Sc. and Ph.D. degrees from Harvard University.

To speak with Dr. Wong about Januvia or other issues regarding the type 2 diabetes drug market, please contact Liz Marshall at 781-296-2563 or

About Decision Resources

Decision Resources, Inc. ( ) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

  All company, brand, or product names contained in this document may be      trademarks or registered trademarks of their respective holders.    For more information, contact:   Elizabeth Marshall   781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,

New Jersey Hospital Market Continues to Experience Financial Hardship

View Now